Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis
Kristy K Broman, Tasha M Hughes, Lesly A Dossett, James Sun, Michael J Carr, Dennis A Kirichenko, Avinash Sharma, Edmund K Bartlett, Amanda AG Nijhuis, John F Thompson, Tina J Hieken, Lisa Kottschade, Jennifer Downs, David E Gyorki, J Jennifer Gyorki, Emma Stahlie, Alexander van Akkooi, David W Ollila, Jill Frank, Yun Song Show all
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS | ELSEVIER SCIENCE INC | Published : 2021
BACKGROUND: In sentinel lymph node (SLN)-positive melanoma, two randomized trials demonstrated equivalent melanoma-specific survival with nodal surveillance vs completion lymph node dissection (CLND). Patients with microsatellites, extranodal extension (ENE) in the SLN, or >3 positive SLNs constitute a high-risk group largely excluded from the randomized trials, for whom appropriate management remains unknown. STUDY DESIGN: SLN-positive patients with any of the three high-risk features were identified from an international cohort. CLND patients were matched 1:1 with surveillance patients using propensity scores. Risk of any-site recurrence, SLN-basin-only recurrence, and melanoma-specific mo..View full abstract
Awarded by NCI
Awarded by National Health and Medical Research Council
Dr Heiken is supported by the Breast Cancer Research Foundation. Dr Sarnaik is supported by NCI Grant 1 K23CA178083-01. Dr Thompson is supported by National Health and Medical Research Council Grant APP1093017.